Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) PT at $14.00

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $12.25.

Several brokerages recently commented on SANA. HC Wainwright raised their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Jefferies Financial Group began coverage on shares of Sana Biotechnology in a research note on Friday. They issued a "buy" rating and a $7.00 price objective for the company. Finally, TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th.

Insider Transactions at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the sale, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 31.10% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology in the third quarter valued at approximately $29,000. Stifel Financial Corp purchased a new stake in Sana Biotechnology in the third quarter valued at approximately $43,000. EP Wealth Advisors LLC purchased a new stake in Sana Biotechnology in the third quarter valued at approximately $45,000. Tower Research Capital LLC TRC grew its holdings in Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after purchasing an additional 10,548 shares during the period. Finally, Cerity Partners LLC purchased a new stake in Sana Biotechnology in the fourth quarter valued at approximately $25,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Stock Up 10.6 %

Shares of NASDAQ SANA traded up $0.28 during midday trading on Friday, hitting $2.93. The company had a trading volume of 2,989,692 shares, compared to its average volume of 2,977,744. Sana Biotechnology has a twelve month low of $1.52 and a twelve month high of $10.50. The business has a 50-day simple moving average of $3.03 and a two-hundred day simple moving average of $3.27. The firm has a market capitalization of $654.18 million, a price-to-earnings ratio of -2.09 and a beta of 1.63.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.